bisoprolol has been researched along with Pulmonary Disease, Chronic Obstructive in 25 studies
Bisoprolol: A cardioselective beta-1 adrenergic blocker. It is effective in the management of HYPERTENSION and ANGINA PECTORIS.
Pulmonary Disease, Chronic Obstructive: A disease of chronic diffuse irreversible airflow obstruction. Subcategories of COPD include CHRONIC BRONCHITIS and PULMONARY EMPHYSEMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To the best of our knowledge, there is no study that has conducted a review investigating the clinical efficacy and safety of bisoprolol combined with trimetazidine on chronic heart failure (CHF) patients with chronic obstructive pulmonary disease (COPD)." | 8.02 | Effects of trimetazidine in combination with bisoprolol in patients with chronic heart failure and concomitant chronic obstructive pulmonary disease: A protocol for systematic review and meta-analysis. ( Fu, B; Ma, S; Zhang, X, 2021) |
| "Chronic obstructive pulmonary disease (COPD) frequently coexists in patients with chronic heart failure (CHF) and is a key factor for beta blocker underprescription and underdosing." | 6.76 | Differences between bisoprolol and carvedilol in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized trial. ( Kovacic, D; Lainscak, M; Podbregar, M; Rozman, J; von Haehling, S, 2011) |
| "-0." | 6.74 | Bisoprolol in patients with heart failure and moderate to severe chronic obstructive pulmonary disease: a randomized controlled trial. ( Carter, R; Chalmers, GW; Dunn, FG; Hawkins, NM; MacDonald, MR; McMurray, JJ; Petrie, MC, 2009) |
| " After adjustment for age, sex, comorbidities, and severity of HF and COPD, bisoprolol use showed a dose-response survival benefit [low dose: adjusted hazard ratio (HR) = 0." | 5.43 | Carvedilol, Bisoprolol, and Metoprolol Use in Patients With Coexistent Heart Failure and Chronic Obstructive Pulmonary Disease. ( Chang, YS; Chen, TJ; Chou, KT; Hu, YW; Hung, MH; Lee, FY; Liu, CJ; Ou, SM; Perng, DW; Su, VY; Yang, KY, 2016) |
| "To study effects of a cardioselective beta-adrenoblocker bisoprolol on vascular wall endothelium and external respiration function in stable angina of effort combined with chronic obstructive pulmonary disease (COPD)." | 5.35 | [Effects of beta 1-adrenoblocker bisoprolol on endothelial dysfunction in patients with stable angina pectoris in combination with chronic obstructive pulmonary disease]. ( Grigor'eva, NIu; Kontorshchikova, KN; Koroleva, EF; Kuznetsov, AN; Mazalov, KV; Sharabrin, EG, 2009) |
| "To compare the hazard of all-cause, chronic obstructive pulmonary disease (COPD) and heart failure (HF) hospitalization in carvedilol vs." | 5.27 | Relationship between heart failure, concurrent chronic obstructive pulmonary disease and beta-blocker use: a Danish nationwide cohort study. ( Andersen, MP; Capuano, A; Enghusen-Poulsen, H; Gislason, G; Mascolo, A; Mortensen, RN; Rosano, GMC; Rossi, F; Sessa, M; Torp-Pedersen, C, 2018) |
| " Based on previous reports, we have launched a multicenter, prospective, single-arm phase II study to evaluate the preventive effect of the cardioselective β-blocker bisoprolol in COPD exacerbation, in Japanese individuals with moderate-to-severe COPD who do not have heart failure but do have hypertension requiring the use of medication." | 5.24 | Protective Effects of Bisoprolol against Acute Exacerbation in Moderate-to-Severe Chronic Obstructive Pulmonary Disease. ( Fujii, U; Ichihara, E; Ichikawa, H; Kanehiro, A; Kiura, K; Miyahara, N; Morichika, D; Oda, N; Oze, I; Taniguchi, A; Tanimoto, M; Tanimoto, Y, 2017) |
| " A comparative study on the efficacy and safety of bisoprolol and sustained release metoprolol succinate in patients with arterial hypertension (AH), cardiovascular disease (CVD) and chronic obstructive pulmonary disease (COPD) was conducted." | 5.19 | [Efficacy and safety of bisoprololal in hypertensive patients with cardiovascular disease and chronic obstructive pulmonary disease]. ( Chernikov, MV; Derevianchenko, MV; Lopushkova, IuE; Statsenko, ME, 2014) |
| "To study effects of a selective beta1-adrenoblocker (B1AB) bisoprolol fumarate (conkor, Nikomed, Germany) on severity of pulmonary hypertension (PH), bronchial obstruction and bioelectric activity of the myocardium in patients with chronic obstructive pulmonary disease (COPD) associated with ischemic heart disease (IHD)." | 5.12 | [Efficacy of a cardioselective beta1-adrenoblocker bisoprolol in patients with chronic obstructive pulmonary disease in combination with ischemic heart disease]. ( Tsvetkova, OA; Veselovskaia, MV, 2007) |
| " The prevalence of hypertension in COPD patients ranges from 39-51%, and β-blockers and amlodipine are commonly used drugs for these patients." | 4.31 | Impact of bisoprolol and amlodipine on cardiopulmonary responses and symptoms during exercise in patients with chronic obstructive pulmonary disease. ( Hsieh, PC; Lan, CC; Su, WL; Tzeng, IS; Wu, CW; Wu, YK; Yang, MC, 2023) |
| "To the best of our knowledge, there is no study that has conducted a review investigating the clinical efficacy and safety of bisoprolol combined with trimetazidine on chronic heart failure (CHF) patients with chronic obstructive pulmonary disease (COPD)." | 4.02 | Effects of trimetazidine in combination with bisoprolol in patients with chronic heart failure and concomitant chronic obstructive pulmonary disease: A protocol for systematic review and meta-analysis. ( Fu, B; Ma, S; Zhang, X, 2021) |
| "Clinical guidelines suggest that for patients with heart failure and concurrent chronic obstructive pulmonary disease (COPD), metoprolol/bisoprolol/nebivolol should be preferred over carvedilol." | 3.91 | Beta-blocker choice and exchangeability in patients with heart failure and chronic obstructive pulmonary disease: an Italian register-based cohort study. ( Andersen, M; Capuano, A; Jensen, MT; Kragholm, K; Mascolo, A; Pagliaro, C; Rafaniello, C; Rasmussen, DB; Rossi, F; Sessa, M; Sportiello, L; Tari, GM, 2019) |
| " No significant adverse effects occurred." | 3.30 | Bisoprolol versus celiprolol on dynamic hyperinflation, cardiopulmonary exercise and domiciliary safety in COPD: a single-centre, randomised, crossover study. ( Anderson, W; Lipworth, BJ; Ross, R; Short, P, 2023) |
| "Chronic obstructive pulmonary disease (COPD) is associated with significant morbidity, mortality and healthcare costs." | 3.11 | Use of the oral beta blocker bisoprolol to reduce the rate of exacerbation in people with chronic obstructive pulmonary disease (COPD): a randomised controlled trial (BICS). ( Abbas, H; Briggs, A; Campbell, K; Chaudhuri, R; Choudhury, G; Cotton, S; Dawson, D; De Soyza, A; Devereux, G; Fielding, S; Gompertz, S; Haughney, J; Lang, CC; Lee, AJ; Lipworth, BJ; MacLennan, G; MacNee, W; McCormack, K; McMeekin, N; Mills, NL; Morice, A; Norrie, J; Petrie, MC; Price, D; Short, P; Vestbo, J; Walker, P; Wedzicha, J; Wilson, A, 2022) |
| "Heart disease in chronic obstructive pulmonary disease (COPD) is a common but neglected comorbidity." | 3.01 | Preventing adverse cardiac events (PACE) in chronic obstructive pulmonary disease (COPD): study protocol for a double-blind, placebo controlled, randomised controlled trial of bisoprolol in COPD. ( Aggarwal, A; Balicki, G; Beasley, R; Chang, CL; Cochrane, B; Di Tanna, GL; Dobler, CC; Farah, CS; Galgey, S; Hancox, RJ; Hillis, GS; Jenkins, C; Martin, A; McDonald, V; Scowcroft, CP; Wrobel, J; Yang, IA, 2021) |
| "Chronic obstructive pulmonary disease (COPD) frequently coexists in patients with chronic heart failure (CHF) and is a key factor for beta blocker underprescription and underdosing." | 2.76 | Differences between bisoprolol and carvedilol in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized trial. ( Kovacic, D; Lainscak, M; Podbregar, M; Rozman, J; von Haehling, S, 2011) |
| "In subjects with COPD, forced expiratory volume in 1 s was lowest with carvedilol and highest with bisoprolol (carvedilol 1." | 2.75 | Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial. ( Coleman, CF; Elsik, M; Hayward, CS; Jabbour, A; Keogh, AM; Kotlyar, E; Krum, H; Macdonald, PS; Mellemkjaer, S, 2010) |
| "-0." | 2.74 | Bisoprolol in patients with heart failure and moderate to severe chronic obstructive pulmonary disease: a randomized controlled trial. ( Carter, R; Chalmers, GW; Dunn, FG; Hawkins, NM; MacDonald, MR; McMurray, JJ; Petrie, MC, 2009) |
| "Chronic obstructive pulmonary disease (COPD) is an inflammatory lung disease involving airway closure and parenchyma destruction (emphysema)." | 1.91 | Elevated Blood Pressure Occurs without Endothelial Dysfunction in a Rat Model of Pulmonary Emphysema. ( Alburquerque, L; Bideaux, P; Bourdin, A; Cazorla, O; Charrabi, A; Desplanche, E; Gouzi, F; Grillet, PE; Virsolvy, A; Wynands, Q, 2023) |
| " Careful monitoring is recommended for possible new symptoms, such as emergence/increase of shortness of breath, cough or changes in dosing of other drugs (for example, increased frequency of using short-acting bronchodilators)." | 1.62 | [Possibilities and limitations of the use of beta-blockers in patients with cardiovascular disease and chronic obstructive pulmonary disease]. ( Karoli, NA; Rebrov, AP, 2021) |
| "Within the COPD GOLD II stage group, there appears to be no statistically significant difference in the number of exacerbations between the patients taking verapamil and digoxin (n = 24) and the patients taking BBs alone (n = 15), although, in patients taking BBs alone, there appears to be a trend towards a decrease in the exacerbations compared to the number of exacerbations in patients taking verapamil and digoxin (p = 0." | 1.51 | Beta-blocker Use in Moderate and Severe Chronic Obstructive Pulmonary Disease. ( Bedak, O; Begic, E; Bradaric, H; Custovic, F; Durak-Nalbantic, A; Hodzic, E; Mujakovic, A; Prnjavorac, B; Zvizdic, F, 2019) |
| "Bisoprolol was found to reduce mortality and CHF exacerbation compared to carvedilol and metoprolol." | 1.46 | The evaluation of β-adrenoceptor blocking agents in patients with COPD and congestive heart failure: a nationwide study. ( Chen, CY; Huang, YB; Kuo, CC; Liao, KM; Lin, TY, 2017) |
| " After adjustment for age, sex, comorbidities, and severity of HF and COPD, bisoprolol use showed a dose-response survival benefit [low dose: adjusted hazard ratio (HR) = 0." | 1.43 | Carvedilol, Bisoprolol, and Metoprolol Use in Patients With Coexistent Heart Failure and Chronic Obstructive Pulmonary Disease. ( Chang, YS; Chen, TJ; Chou, KT; Hu, YW; Hung, MH; Lee, FY; Liu, CJ; Ou, SM; Perng, DW; Su, VY; Yang, KY, 2016) |
| "Acute decompensated HF patients with COPD were classified according to the oral drug used at discharge into β-blocker (n=86; carvedilol [n=52] or bisoprolol [n=34]) and non-β-blocker groups (n=46)." | 1.42 | Impact of β-blocker selectivity on long-term outcomes in congestive heart failure patients with chronic obstructive pulmonary disease. ( Asai, K; Furuse, E; Kubota, Y; Murai, K; Nakamura, S; Shimizu, W; Tsukada, YT, 2015) |
| "To study effects of a cardioselective beta-adrenoblocker bisoprolol on vascular wall endothelium and external respiration function in stable angina of effort combined with chronic obstructive pulmonary disease (COPD)." | 1.35 | [Effects of beta 1-adrenoblocker bisoprolol on endothelial dysfunction in patients with stable angina pectoris in combination with chronic obstructive pulmonary disease]. ( Grigor'eva, NIu; Kontorshchikova, KN; Koroleva, EF; Kuznetsov, AN; Mazalov, KV; Sharabrin, EG, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (16.00) | 29.6817 |
| 2010's | 14 (56.00) | 24.3611 |
| 2020's | 7 (28.00) | 2.80 |
| Authors | Studies |
|---|---|
| Karoli, NA | 1 |
| Rebrov, AP | 1 |
| Cotton, S | 1 |
| Devereux, G | 1 |
| Abbas, H | 1 |
| Briggs, A | 1 |
| Campbell, K | 1 |
| Chaudhuri, R | 1 |
| Choudhury, G | 1 |
| Dawson, D | 1 |
| De Soyza, A | 1 |
| Fielding, S | 1 |
| Gompertz, S | 1 |
| Haughney, J | 1 |
| Lang, CC | 1 |
| Lee, AJ | 1 |
| MacLennan, G | 1 |
| MacNee, W | 1 |
| McCormack, K | 1 |
| McMeekin, N | 1 |
| Mills, NL | 1 |
| Morice, A | 1 |
| Norrie, J | 1 |
| Petrie, MC | 2 |
| Price, D | 1 |
| Short, P | 2 |
| Vestbo, J | 1 |
| Walker, P | 1 |
| Wedzicha, J | 1 |
| Wilson, A | 1 |
| Lipworth, BJ | 2 |
| Lan, CC | 1 |
| Hsieh, PC | 1 |
| Tzeng, IS | 1 |
| Yang, MC | 1 |
| Wu, CW | 1 |
| Su, WL | 1 |
| Wu, YK | 1 |
| Anderson, W | 1 |
| Ross, R | 1 |
| Desplanche, E | 1 |
| Grillet, PE | 1 |
| Wynands, Q | 1 |
| Bideaux, P | 1 |
| Alburquerque, L | 1 |
| Charrabi, A | 1 |
| Bourdin, A | 1 |
| Cazorla, O | 1 |
| Gouzi, F | 1 |
| Virsolvy, A | 1 |
| Sessa, M | 2 |
| Mascolo, A | 2 |
| Rasmussen, DB | 1 |
| Kragholm, K | 1 |
| Jensen, MT | 1 |
| Sportiello, L | 1 |
| Rafaniello, C | 1 |
| Tari, GM | 1 |
| Pagliaro, C | 1 |
| Andersen, M | 1 |
| Rossi, F | 2 |
| Capuano, A | 2 |
| Zvizdic, F | 1 |
| Begic, E | 1 |
| Mujakovic, A | 1 |
| Hodzic, E | 1 |
| Prnjavorac, B | 1 |
| Bedak, O | 1 |
| Custovic, F | 1 |
| Bradaric, H | 1 |
| Durak-Nalbantic, A | 1 |
| Zhang, X | 1 |
| Ma, S | 1 |
| Fu, B | 1 |
| Martin, A | 1 |
| Hancox, RJ | 1 |
| Chang, CL | 1 |
| Beasley, R | 1 |
| Wrobel, J | 1 |
| McDonald, V | 1 |
| Dobler, CC | 1 |
| Yang, IA | 1 |
| Farah, CS | 1 |
| Cochrane, B | 1 |
| Hillis, GS | 1 |
| Scowcroft, CP | 1 |
| Aggarwal, A | 1 |
| Di Tanna, GL | 1 |
| Balicki, G | 1 |
| Galgey, S | 1 |
| Jenkins, C | 1 |
| Liao, KM | 1 |
| Lin, TY | 1 |
| Huang, YB | 1 |
| Kuo, CC | 1 |
| Chen, CY | 1 |
| Taniguchi, A | 1 |
| Miyahara, N | 1 |
| Oda, N | 1 |
| Morichika, D | 1 |
| Ichihara, E | 1 |
| Oze, I | 1 |
| Tanimoto, Y | 1 |
| Ichikawa, H | 1 |
| Fujii, U | 1 |
| Tanimoto, M | 1 |
| Kanehiro, A | 1 |
| Kiura, K | 1 |
| Mortensen, RN | 1 |
| Andersen, MP | 1 |
| Rosano, GMC | 1 |
| Gislason, G | 1 |
| Enghusen-Poulsen, H | 1 |
| Torp-Pedersen, C | 1 |
| Statsenko, ME | 1 |
| Derevianchenko, MV | 1 |
| Chernikov, MV | 1 |
| Lopushkova, IuE | 1 |
| Kubota, Y | 1 |
| Asai, K | 1 |
| Furuse, E | 1 |
| Nakamura, S | 1 |
| Murai, K | 1 |
| Tsukada, YT | 1 |
| Shimizu, W | 1 |
| Su, VY | 1 |
| Chang, YS | 1 |
| Hu, YW | 1 |
| Hung, MH | 1 |
| Ou, SM | 1 |
| Lee, FY | 1 |
| Chou, KT | 1 |
| Yang, KY | 1 |
| Perng, DW | 1 |
| Chen, TJ | 1 |
| Liu, CJ | 1 |
| Grigor'eva, NIu | 3 |
| Sharabrin, EG | 1 |
| Kuznetsov, AN | 1 |
| Mazalov, KV | 1 |
| Kontorshchikova, KN | 1 |
| Koroleva, EF | 1 |
| Hawkins, NM | 1 |
| MacDonald, MR | 1 |
| Chalmers, GW | 1 |
| Carter, R | 1 |
| Dunn, FG | 1 |
| McMurray, JJ | 1 |
| Jabbour, A | 1 |
| Macdonald, PS | 1 |
| Keogh, AM | 1 |
| Kotlyar, E | 1 |
| Mellemkjaer, S | 1 |
| Coleman, CF | 1 |
| Elsik, M | 1 |
| Krum, H | 1 |
| Hayward, CS | 1 |
| Ageev, FT | 1 |
| Makarova, GV | 1 |
| Patrusheva, IF | 1 |
| Orlova, IaA | 1 |
| Lainscak, M | 1 |
| Podbregar, M | 1 |
| Kovacic, D | 1 |
| Rozman, J | 1 |
| von Haehling, S | 1 |
| Mainguy, V | 1 |
| Girard, D | 1 |
| Maltais, F | 1 |
| Saey, D | 1 |
| Milot, J | 1 |
| Sénéchal, M | 1 |
| Poirier, P | 1 |
| Provencher, S | 1 |
| Stiefelhagen, P | 1 |
| Tsvetkova, OA | 1 |
| Veselovskaia, MV | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Preventing Adverse Cardiac Events in Chronic Obstructive Pulmonary Disease[NCT03917914] | Phase 3 | 280 participants (Actual) | Interventional | 2020-06-30 | Active, not recruiting | ||
| Cardioselective Beta-Blockade Using Bisoprolol in Patients With Chronic Heart Failure (CHF) and Coexistent Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) With or Without Significant Reversibility.[NCT00702156] | Phase 2 | 27 participants (Actual) | Interventional | 2005-03-31 | Terminated (stopped due to Inadequate patient recruitment) | ||
| Heart Rate Lowering Efficacy and Respiratory Safety of Ivabradine in Patients With Obstructive Airway Disease[NCT01365286] | Phase 4 | 40 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
12 trials available for bisoprolol and Pulmonary Disease, Chronic Obstructive
| Article | Year |
|---|---|
Use of the oral beta blocker bisoprolol to reduce the rate of exacerbation in people with chronic obstructive pulmonary disease (COPD): a randomised controlled trial (BICS).
Topics: Adrenal Cortex Hormones; Adrenergic beta-Antagonists; Adult; Anti-Bacterial Agents; Bisoprolol; Dise | 2022 |
Bisoprolol versus celiprolol on dynamic hyperinflation, cardiopulmonary exercise and domiciliary safety in COPD: a single-centre, randomised, crossover study.
Topics: Bisoprolol; Celiprolol; Cross-Over Studies; Exercise Tolerance; Humans; Pulmonary Disease, Chronic O | 2023 |
Preventing adverse cardiac events (PACE) in chronic obstructive pulmonary disease (COPD): study protocol for a double-blind, placebo controlled, randomised controlled trial of bisoprolol in COPD.
Topics: Bisoprolol; Disease Progression; Double-Blind Method; Forced Expiratory Volume; Humans; Pulmonary Di | 2021 |
Protective Effects of Bisoprolol against Acute Exacerbation in Moderate-to-Severe Chronic Obstructive Pulmonary Disease.
Topics: Antihypertensive Agents; Bisoprolol; Clinical Studies as Topic; Humans; Hypertension; Japan; Pulmona | 2017 |
Relationship between heart failure, concurrent chronic obstructive pulmonary disease and beta-blocker use: a Danish nationwide cohort study.
Topics: Adrenergic beta-1 Receptor Agonists; Aged; Bisoprolol; Carvedilol; Cause of Death; Comorbidity; Denm | 2018 |
[Efficacy and safety of bisoprololal in hypertensive patients with cardiovascular disease and chronic obstructive pulmonary disease].
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Antihypertensive Agents; Bisoprolol; Cardiovascular Di | 2014 |
Bisoprolol in patients with heart failure and moderate to severe chronic obstructive pulmonary disease: a randomized controlled trial.
Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Blood Gas Analysis; Comorbidity; Double-Blind Method; | 2009 |
Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Carbazoles; Carvedilol; Chr | 2010 |
[The efficacy and safety of the combination of β-blocker bisoprolol and if inhibitor I(f) ivabradine in patients with stable angina and chronic obstructive pulmonary disease].
Topics: Administration, Inhalation; Adrenergic beta-1 Receptor Antagonists; Aged; Angina Pectoris; Benzazepi | 2010 |
Differences between bisoprolol and carvedilol in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized trial.
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Bisoprolol; Carbazoles; Carvedilol; Chro | 2011 |
Effect of bisoprolol on respiratory function and exercise capacity in chronic obstructive pulmonary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Bisoprolol; Blood Pressure; Cross-Over Studies; Double | 2012 |
[Efficacy of a cardioselective beta1-adrenoblocker bisoprolol in patients with chronic obstructive pulmonary disease in combination with ischemic heart disease].
Topics: Adrenergic beta-Antagonists; Bisoprolol; Blood Gas Analysis; Female; Heart Conduction System; Humans | 2007 |
13 other studies available for bisoprolol and Pulmonary Disease, Chronic Obstructive
| Article | Year |
|---|---|
[Possibilities and limitations of the use of beta-blockers in patients with cardiovascular disease and chronic obstructive pulmonary disease].
Topics: Adrenergic beta-Antagonists; Bisoprolol; Cardiovascular Diseases; Heart Failure; Humans; Pulmonary D | 2021 |
Impact of bisoprolol and amlodipine on cardiopulmonary responses and symptoms during exercise in patients with chronic obstructive pulmonary disease.
Topics: Adrenergic beta-Antagonists; Amlodipine; Bisoprolol; Exercise Test; Humans; Hypertension; Pulmonary | 2023 |
Elevated Blood Pressure Occurs without Endothelial Dysfunction in a Rat Model of Pulmonary Emphysema.
Topics: Animals; Bisoprolol; Blood Pressure; Emphysema; Heart Failure; Hypertension; Male; Pulmonary Disease | 2023 |
Beta-blocker choice and exchangeability in patients with heart failure and chronic obstructive pulmonary disease: an Italian register-based cohort study.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Atrioventricular Block; Bisoprolol; Carvedilol | 2019 |
Beta-blocker Use in Moderate and Severe Chronic Obstructive Pulmonary Disease.
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Bisoprolol; Case-Control | 2019 |
Effects of trimetazidine in combination with bisoprolol in patients with chronic heart failure and concomitant chronic obstructive pulmonary disease: A protocol for systematic review and meta-analysis.
Topics: Adrenergic beta-1 Receptor Antagonists; Bisoprolol; Chronic Disease; Drug Therapy, Combination; Hear | 2021 |
The evaluation of β-adrenoceptor blocking agents in patients with COPD and congestive heart failure: a nationwide study.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Bisoprolol; Carbazoles; Carvedilol; Chi-Square | 2017 |
Impact of β-blocker selectivity on long-term outcomes in congestive heart failure patients with chronic obstructive pulmonary disease.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Aged, 80 and over; Bisoprolol; Carbazoles; Carvedilol | 2015 |
Carvedilol, Bisoprolol, and Metoprolol Use in Patients With Coexistent Heart Failure and Chronic Obstructive Pulmonary Disease.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Carbazoles; Carvedilol; Con | 2016 |
[Effects of beta 1-adrenoblocker bisoprolol on endothelial dysfunction in patients with stable angina pectoris in combination with chronic obstructive pulmonary disease].
Topics: Adrenergic beta-Antagonists; Aged; Angina Pectoris; Bisoprolol; Endothelium, Vascular; Female; Human | 2009 |
[Efficacy of therapy with bisoprolol and ivabradine in patients with ischemic heart disease combined with chronic obstructive pulmonary disease assessment of parameters of 24-hour ECG monitoring].
Topics: Adrenergic beta-Antagonists; Aged; Benzazepines; Bisoprolol; Bronchoconstriction; Cyclic Nucleotide- | 2009 |
[COPD patients with heart failure: no concern about the beta blocker!].
Topics: Adrenergic Agents; Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Comorbidity; Con | 2012 |
[Assessment of therapeutic equivalence of original bisoprolol and its generics in patients with ischemic heart disease with concomitant chronic obstructive pulmonary disease].
Topics: Adult; Aged; Biological Availability; Bisoprolol; Comorbidity; Drug Monitoring; Drug Substitution; D | 2012 |